Brief: Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma
02/04/2025 14:07
April 2 (Reuters) - Alpha Tau Medical Ltd DRTS.O: ALPHA TAU RECEIVES FDA APPROVAL TO INITIATE A TRIAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA Source text: ID:nGNX9xf9q5 Further company coverage: DRTS.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Alpha Tau Medical
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Brief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026